Integrative genomics strategies to elucidate the complexity of drug response Interindividual variability in drug response, adverse events and toxicity represents a common observation in clinical therapeutics, and strong genetic components underlying drug metabolism and clinical drug response have been implicated through family and twin studies [1] [2] [3] [4] [5] [6] [7] . Understanding the genetic factors that predispose patients to poor treatment outcome, adverse events and/or toxicity will help guide therapeutic strategies for individual patients to obtain maximal efficacy and safety. With genome-wide geno typing of common variation becoming routine, and whole exome and even whole-genome sequencing beginning to emerge as an affordable practice in research settings, the study of the relationship between genetic variations (primarily SNPs) and drug response or toxicity has shifted from limited numbers of candidate variations (pharmacogenetics) to whole-genome variation that covers hundreds of thousands to millions of SNPs simultaneously (pharmacogenomics). Whole-genome scanning provides a far more objective and comprehensive view of the genetic susceptibility of drug response than previous knowledge-based candidate-gene approaches, just as it has in the genetic study of common human diseases.
Pharmacogenomic studies have identified genetic markers that are strong predictors of drug effects [8] . For instance, common and rare genetic variations in CYP2C9 and VKORC1 are found to predict warfarin dosage or response [9] [10] [11] [12] [13] , the HLA-B*5701 variant is associated with abacavir hypersensitivity [14, 15] , HLA-B*5701, HLA-DRB1*0107-DRB1*0103, and TNF-a-238G/A are linked to flucloxacillin-induced liver injury [16] , and SNPs at the IL28A/IL28B locus are associated with antihepatitis C treatment response to interferons and ribavirin [17] [18] [19] [20] . These findings highlight the power of pharmacogenomics to identify genetic risk factors. However, the identification of susceptibility SNPs or loci does not directly lead to mechanisms, as shown by a survey of genetic loci associated with common human disease [21] . In fact, drug response is a complex trait just like common human disease traits, and so interpretations of genetic associations with drug Pharmacogenomic investigation from both genome-wide association studies and experiments focused on candidate loci involved in drug mechanism and metabolism has yielded a substantial and increasing list of robust genetic effects on drug therapy in humans. At the same time, reasonably comprehensive molecular data such as gene expression, proteomic and metabolomic data are now available for collections of hundreds to thousands of individuals. If these data are structured in a statistically robust and computationally tractable way, such as a network model, they can aid in the analysis of new pharmacogenomics studies by suggesting novel hypotheses for the regulation of genes involved in drug metabolism and response. Similarly, hypotheses taken from these same models can direct genome-wide association studies by focusing the genome-wide association studies analysis on a number of specific hypotheses informed by the relationships customarily seen between a gene's expression or protein activity and genetic variation at a particular locus. Network models based on other sorts of systematic biological data such as cell-based surveys of drug effect on gene expression and mining of literature and electronic medical records for associations between clinical and molecular phenotypes also promise similar utility. Although surely primitive in comparison with what will be developed, these model-based approaches to leveraging the increasing volume of data generated in the course of patient care and medical research nevertheless suggest a huge opportunity to improve our understanding of biological systems involved in pharmacogenomics and apply them to questions of medical relevance.
KEYWORDS: abacavir n Bayesian network n coexpression network n connectivity map n electronic medical records n flucloxacillin n gene networks n genetics of gene expression n genome sequencing n genome-wide association study n integrative genomics n interferons n lumiracoxib n pharmacogenomics n ribavirin n statins n warfarin future science group Review Kasarskis, Yang & Schadt response and disease traits are necessarily similar. In both cases, genome-wide association studies (GWAS) have revealed a definitive relationship between a segment of DNA and a phenotype of interest, a key fact, which is very hard to establish for common genetic variation before GWAS were possible, and that points the way toward fine mapping, functional, and other experiments needed to determine exactly how the DNA variation influences phenotype. Typically, given an association between SNP genotypes from a GWAS and drug response, the gene that is driving variations in response is often unknown. In addition, whether activation or inactivation of that gene leads to increased drug response is often unknown and neither the context in which the associated gene operates nor the mechanism by which the SNP (or causal variants linked to the associated SNP) confers risk of poor response, adverse events or toxicity is clear; therefore there remains ample further experimental work to be done.
According to the GWAS catalog maintained by the National Human Genome Research Institute [22, 201] , a total of 48 pharmacogenomic GWAS have reported the pharmacogenomics of various therapeutic agents in terms of dosage, therapeutic efficacy, adverse events or hepatotoxicity. These studies cover a variety of therapeutic agents including antipsychotics [23] [24] [25] [26] [27] [28] [29] , antidepressants [30] [31] [32] [33] , anticoagulants [11, [34] [35] [36] [37] , anti-hepatitis C drugs [18] [19] [20] , statins [38, 39] and others (Table 1) . In contrast to these successful cases, the results from many other pharmacogenomics studies, especially those for the antidepressant and antipsychotic agents, appear to involve multiple loci, with many loci supported by only a single study [201] , suggesting more complex genetic susceptibility and/or a more complex phenotype affected by many distinct biological processes. In addition, many of the genetic loci are located in intergenic regions with no obvious candidate genes directly implicated, which is consistent with the previous observation that almost 40% of disease/trait-associated SNPs are located in intergenic regions and another 40% are intronic, whereas only 12% are located in or are close to protein-coding regions of genes [21] . Therefore, interpreting pharmacogenomic findings is rarely a straightforward task Recently, integrative genomics approaches that leverage functional genomics and network biology have been developed to identify genes, pathways and gene networks that underlie GWAS findings for various diseases and traits [40] [41] [42] [43] [44] [45] [46] [47] . These methods also exploit a large volume of valuable information gathered in a GWAS, which is underutilized when the GWAS is analyzed in isolation. Typically, without a prior hypothesis with which to focus the analysis on a subset of gene regions, the multiple testing correction utilized in genome-wide statistical analysis allows for the detection of only the strongest effects, and penalizes weaker associations that are biologically meaningful. In this review, we discuss several integrative genomics methodologies that are just as applicable to the pharmacogenomics field as they are in the study of common human disease and systems biology more generally, where they were largely developed.
Functional genomics
As discussed above, genetic association studies such as pharmacogenomics or GWAS investigate the association between genetic variations and clinical diseases or traits to uncover genetic risk factors of phenotypic traits. However, although the identification of significant genetic loci from a genetic association study does imply that they are functionally relevant to the associated pheno type, it does not directly imply functional relevance of the associated SNPs or provide the under lying genes and molecular mechanisms, except in those cases where the genetic polymorphism has an obvious path to mechanism such as structural effect on a protein. In order to tackle the functional role of the risk loci, it is necessary to not only understand the corresponding genes involved, but also to understand the molecular consequences of the sequence variations. To this end, the relationship between the genome and intermediate molecular traits such as gene expression, alternative splicing and protein products can be explored via functional genomic studies to identify molecular quantitative trait loci (QTL).
The study of genetic variations that are associated with gene expression, the most commonly characterized molecular trait, is coined genetics of gene expression (GGE). Through GGE, one can simultaneously scan for associations between millions of SNPs and tens of thousands of geneexpression traits (including alternative splicing) corresponding to tens of thousands of genes in the human genome, and thereby determine which genetic loci are linked to the expression traits. These genetic loci are termed expression QTL (eQTL), and individual SNPs under eQTL are named expression SNPs (eSNPs). These eQTL or eSNPs linking to intermediate molecular traits are useful in elucidating the functions of the genetic variations. The correlation between a SNP and a molecular trait implies that either the SNP itself or a DNA variant in future science group
Integrative genomics strategies to elucidate the complexity of drug response Review linkage disequilibrium (LD) with the observed SNP is functional. When the same genetic loci or SNPs are found to be associated with a phenotypic trait, the genes whose expression levels are correlated with these QTL or SNPs represent more plausible candidate causal genes for the phenotypic traits than uncorrelated genes [48] [49] [50] [51] [52] [53] [54] [55] [56] . Put simply, it is difficult to imagine how a DNA variation could cause a phenotype without modifying the expression of at least one gene in one tissue, so genes for which eQTL are detected should have a better than random chance of causing the phenotype.
GGE studies have been conducted in lymphocytes or lymphoblastoid cell lines [57] [58] [59] [60] [61] [62] [63] [64] [65] , monocytes [66] , fibroblasts [67] , T-cells [67] , brain [68] , liver [42, 69] and adipose tissues [41, 58, 69] . These studies support the presence of both shared eQTL across tissues or cell types and tissue-or cell-type-specific eQTL. The overlap of eQTL across tissues has been found to depend on both sample size and similarity between tissues. As reported by Greenawalt et al. [69] with a sample size of approximately 100, approximately 30% of eQTL overlap between liver and adipose, and 49% overlap between subcutaneous adipose and It is important to note that eQTL identification is subject to confounders that produce nonreplicable false discoveries and that replication between studies is therefore critical in order to select eQTL of biological significance. In a recent study, Innocenti et al. investigated eQTL in two independent liver cohorts and found that confounders that affect liver gene expression, such as drug exposure, clinical descriptors and unknown factors associated with tissue ascertainment and analysis, and all contribute to the ability to replicate eQTL between studies [70] . Therefore, thorough quality control and advanced statistical methods that take hidden cofounding variables into consideration are necessary to identify reliable signals.
In addition to eQTL identified in GGE studies, QTL for other intermediate molecular traits such as alternative splicing [60, [71] [72] [73] allelic expression [74, 75] , DNA methylation [76] [77] [78] [79] [80] [81] , and liver enzyme activity [82] have also been pursued and similar tissue specificities have been observed for these molecular QTL types. Additional types of molecular QTL associated with traits such as miRNA, protein and metabolite levels, histone modification and chromatin structure can also be detected to further annotate the function of genetic loci.
The power of utilizing QTL of molecular traits identified from functional genomic studies to identify candidate genes as well as the mechanisms underlying GWAS findings of complex human diseases have been demonstrated in a number of recent studies [40] [41] [42] 72] . For example, the HLA-DRB1 locus identified for Type 1 diabetes is strongly associated with the expression levels of the HLA-DRB1 gene [42, 69] . In the case of warfarin treatment, a SNP approximately 50 kb upstream of the gene VKORC1, rs10871454, was found to be associated with warfarin dosage with an association p-value of 4.7 × 10 -34 in a meta-analysis of index and replication cohorts in a recent pharmacogenomics GWAS [35] . As this SNP is in perfect LD (r 2 = 1.0) with the promoter SNP rs9923231, it could act as a surrogate for the promoter SNP, which functions in regulating the expression of VKORC1. In order to elucidate the potential mechanism, we searched our human liver eSNP database and found that this SNP is strongly associated with the expression level of VKORC1 at p = 1.07 × 10 -69 [42, 69] . Specifically, the minor allele of rs10871454 is associated with decreased VKORC1 expression (Figure 1 ). This finding suggests that rs10871454 itself or one or more functional DNA variants in LD with this SNP regulate the expression levels of the warfarin target gene, thus providing a mechanistic explanation for the observed association between the SNP and warfarin response. The liver eSNPs from two cohorts, an unselected liver cohort [42] and a morbidly obese cohort [69] , have been published and are publicly accessible. The expression data for both cohorts are available at Gene Expression Omnibus [202] with accession numbers GSE9588 and GSE24335. The genotype data can be obtained upon request and will be available at dbGaP [203] . Between the two cohorts, 66% of eSNPs overlap, suggesting consistent signals. We chose to report the SNP-gene association p-values from the larger liver cohort due to its higher statistical power [70] .
When intersecting the genetic loci identified from other recent pharmacogenomics GWAS listed in Table 1 with published liver GGE or eQTL data [42, 69] , we were able to identify or confirm additional candidate genes for a number of loci via eQTL mapping. For example, the HLA-DRB1 locus for lumiracoxib-related liver injury [83] is found to be a liver eQTL for the HLA-DRB1 gene (p = 3.15 × 10 -33 for association of SNP rs3129934 and HLA-DRB1 gene expression). In addition, several loci for statin response or adverse effects [38, 39, 84] and HLA-C (p = 1.90 × 10 -6 ). Although these eSNP-gene associations were identified from published eQTL studies, these associations have not been highlighted previously in the context of pharmacogenomics, with the exception of the VKORC1 association. Tables 1 & 2 list all of the genes significantly associated with pharmacogenomics GWAS SNPs as this association provides empirical evidence to support them as candidate genes at these loci. Whether or not these eSNP-nominated candidate genes do in fact mediate the association with phenotype future science group
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Review Kasarskis, Yang & Schadt will, of course, await further confirmatory experiments of the type performed to nominate SORT1 as the causal gene underlying the 1p13 human dyslipidemia locus [85] .
It is worth noting that many loci could not be successfully mapped via GGE in these liver data sets. One possible explanation for this is that the effect of these loci on the expression of genes in the liver is small, and that the loci negative for regulation of gene expression in the liver might demonstrate that regulation in other tissues. Another possibility is that many loci may affect the function of a gene via post-transcriptional mechanisms that are not detected at the level of gene expression or eQTL. Still another possibility is that many of the pharmacogenomic associations that have been reported may represent false discoveries, as is suggested for those that have not been reproduced in independent studies. All of these effects demonstrate an opportunity to improve the use of functional genomics in interpreting pharmacogenomics studies.
Network biology
While helpful when inferring the candidate genes underlying individual genetic loci via QTL mapping as demonstrated in the previous section, functional genomics cannot, in general, directly address the molecular mechanisms of each locus as well as the potential interactions among genetic loci. In recent years, network biology has increasingly come to provide a systems view of how individual molecular traits such as genes, metabolites or proteins interact with one another and their relationship with various clinical phenotypes (including drug response) within a cell, a tissue or an organ via integration of large-scale genetic, genomic, transcriptomic, metabolomic and proteomic data [86] . As shown in Figure 2 , networks are represented graphically as nodes and edges, where nodes are individual molecular traits or higher-order phenotypes (e.g., clinical traits associated with disease) and edges represent the interactions such as physical binding or statistical correlation among mole cular traits or between molecular traits and higher-order phenotypes. Networks can be directed or undirected. In a directed network, the direction of an edge between any two nodes represents a causal relationship or a sequential event, whereas in an undirected network the edge between two nodes represents reciprocal association such as correlation.
A variety of network methodologies have been developed to construct networks of various types. The most common networks are protein-protein interaction networks and gene regulatory networks. In this review, we will focus initially on two types of gene regulatory networks, namely, weighted gene coexpression network analysis (WGCNA) [87, 88] and Bayesian network (BN) (Figure 3 ) [89] [90] [91] [92] [93] [94] [95] [96] . We have constructed such networks in various species including human, mouse and yeast to help identify gene sub-networks associated with a variety of common human diseases such as obesity and atherosclerosis [16, [97] [98] [99] [100] 204] .
WGCNA is a correlation-based method and focuses on the coregulation pattern among genes. The advantage of coexpression networks is that they allow one to look at the overall gene-gene correlation structure at a high level via the construction of gene modules comprised of highly interconnected sets of genes (a schematic analysis flow is shown in Figure 3a) . A number of studies have demonstrated that coexpression network modules are generally enriched for genes involved in known biological pathways, for genes that are linked to common genetic loci, and for genes associated with diseases [42, 51, 87, [97] [98] [99] [100] [101] [102] [103] [104] [105] . Using coexpression networks, one can identify key groups of genes that are modulated by genetic loci or regulated by key transcription factors and that in turn lead to disease, and therefore define disease states at the molecular level [89] .
BNs on the other hand are probabilistic graphical models comprised of molecular and higher-order traits and constructed by assessing the conditional dependencies between all of the variables under consideration (a schematic analysis flow is shown in Figure 3b) . A BN provides a natural and mathematically elegant framework for integrating diverse large-scale, high-dimensional genetic, transcriptomic, proteomic and metabolomic data sets to decipher the biological function of individual genes and pathways. Prior information such as genetic regulation, transcription factor binding and protein-protein interaction can be incorporated to help infer directionality between genes. Compared with WGCNA, BNs are more sparse since they penalize complexity and therefore only keep primary interactions, however, they allow a more granular view of the relationships and directional predictions between genes than can be obtained with WGCNA [95, 102] . A number of studies performed by us and others in a variety of species have demonstrated that predictive networks such as BN can capture fundamental properties of complex systems in states that give rise to complex phenotypes [42, 82, [89] [90] [91] 95, 96, 102, [106] [107] [108] [109] [110] . Both types of networks provide objective views future science group
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Integrative genomics of the human liver
As liver is the most relevant tissue for the pharmacology of many drugs, functional variations and molecular networks of this tissue are of particular interest for pharmacogenomics. In two recent studies, Schadt et al. [42] and Yang et al. [82] investigated the genetic architecture of liver gene expression, the enzyme activities of CYPs, and the network properties using approximately 500 human liver samples. Through GGE analysis, more than 3000 eQTL for over 6000 distinct liver genes were reported, among which hundreds of genes encode drug-metabolizing enzymes and transporters. In addition to GGE analysis, the genetics of the activity measures of nine key drug-metabolizing P450 enzymes (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) were also studied. With the exception of CYP2E1, each of these P450 enzymes showed variation in activity as a function of genotype in this sample, and these relationships defined 54 activity SNPs in this cohort. Many eSNPs and activity SNPs identified represent novel discoveries. For instance, three novel long-range SNPs were found to be associated with both the expression and the enzyme activity measurements of CYP2D6 in this liver cohort and were confirmed to be associated with the metabolism of dextromethorphan in vivo in an independent human cohort. These eSNPs and activity SNPs discovered from the human liver studies are of importance for pharmacogenomics as they help to understand the impact of individual genetic variants on drugmetabolizing enzymes, transporters and liver drug targets and in addition, help identify plausible candidate genes underlying the genetic loci associated with pharmacogenomic outcomes. Using the WGCNA and BN network methodologies and the genetic and gene-expression data, coexpression and BN networks have been constructed from the same human liver cohort to illustrate the gene regulatory network structure in the human liver [82] . A total of eight coexpression network modules comprised of genes with similar biological functionalities were identified and genes involved in particular functional categories such as immune response, cell cycle and metabolic pathways were enriched in several modules. Four modules enriched for P450 genes, genes involved in oxidative stress and apoptosis, acute-phase response genes and translationrelated genes were found to be highly correlated with P450 expression and activity. Through integration of GGE, two of the four modules were implicated as upstream regulatory modules for P450s. These modules and the genes within them provide additional insights into the regulation of P450s. In addition, BN subnetworks which incorporated both genetic and gene-expression information helped identify a P450 regulatory BN subnetwork. Novel candidate P450 regulatory genes including EHHADH, SLC10A1 and AKR1D1 were highlighted from the analyses of both networks. Although in silico validation of the P450 regulatory subnetwork has been presented, the novel regulators nominated are still under experimental validation.
In addition to gene regulatory networks, metabolic networks of the liver and hepatocytes have also been recently constructed based on literature, transcriptomic, proteomic, metabolomic and phenotypic data to help understand liver metabolism and physiology [111] [112] [113] . These liver networks provide a framework for understanding how a given gene interacts with other genes and how together these genes may impact Drug, disease, gene expression and genetic data generated in different combinations in coherent data sets produce reference networks that can be accessed by unique queries and inform on distinct biological relationships. Specific examples of each network type, methods used to generate them, and references are provided in the text. Gene expression and genetics networks include the weighted gene coexpression network analysis and Bayesian network approaches described under 'Network biology', and the remainder are described in the 'Other integrative genomics approaches to data' section.
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Other integrative genomics approaches to data
As these liver metabolism network studies demonstrate, networks useful in an integrative genomics strategy such as described for human liver are by no means limited to GGE and genetics of drug response traits. In fact, almost any combination of sufficiently rich, coherent and orthogonal data in comparable subjects may be used to derive a biological network model that could be useful when referenced to interpret a pharmacogenomic experiment (Figure 2) . Most obvious are networks that incorporate the effect of drugs on the expression of genes. Early surveys of the expression of compendia of compounds on gene expression have utility and describe basic networks, even if their results were at first not expressly modeled as networks. Examples of this category include a compendium of chemical signatures as well as individual toxin signatures in yeast [114, 115] and the effect of xenobiotic compounds in rat liver [116, 117] . These early efforts clearly demonstrated that drugs have an impact on gene expression and that they could be classified by that expression. Subsequent publications referencing these early networks demonstrated the value of referencing them to draw conclusions regarding basic biology and drug action [55, [118] [119] [120] .
More recently, systematic efforts to screen drugs in mammalian cells and model them in network-based ways have become a reality. The NCI made substantial efforts in this area early on by developing a panel of 60 human tumor cell lines representing tumors from nine tissues and funding diverse experiments to characterize them with many molecular techniques under diverse experimental conditions [121, 122] . These cell lines were also SNP genotyped, allowing genome-wide association studies with all the molecular traits measured in the NCI60 cell lines, and similar association studies have been performed with cellular phenotypes measured in the HapMap human cell lines used to benchmark human genetic variation [123] . The end result of all of this investment has been networks encompassing phenotypic response A connection matrix is then derived from the correlation matrix by defining connectivity using a correlation threshold. For example, at a correlation coefficient of absolute value of over 0.6, all gene pairs that reach this threshold are defined as being connected. The connectivity matrix is then clustered and a dynamic cut-tree algorithm applied to construct the coexpression network and define network modules. Each network module consists of genes that are highly interconnected with one another. (B) Bayesian network (BN) workflow. Joint probability distribution of genes based on the conditional dependencies is calculated to identify a maximum likelihood network given the observed data. Prior information such as genetic regulation, transcription factor binding and protein-protein interaction can then be incorporated to infer directionality between genes. Examples of WGCNA and BN analysis applied to biological data sets and references to the analysis methods themselves are given in the text.
Review Kasarskis, Yang & Schadt to many natural products, experimental compounds, US FDA-approved anticancer agents, gene expression and genetics that has in turn shown relationships between genetic loci, proliferation and viability phenotypes, and drugs such as statins and paclitaxel in these cells [124, 125] .
Among the most popular of these efforts is the connectivity map (cmap), a systematic effort to profile the effect of compounds in human cell lines and then make the results accessible to a broad community of bioinformaticians and bench laboratory researchers [118, 126] . A current download of the cmap database contains information on 1309 compounds in five cancer cell lines, for a total of 6100 combinations, each assayed by gene-expression microarray. Although the genetic and phenotypic diversity of the cell lines is limited, the number of compounds profiled and the accessibility of the data are unprecedented. Accordingly, the cmap has featured in publications seeking to understand the mechanisms by which drugs act and their linkage to disease phenotypes and biological processes. For example, the map has been used to support mechanistic studies of trastuzumab desensitization in breast cancer and extended to identify combinatorial effects between retinoids and histone deacetylase inhibitors in promoting differentiation and increasing survival in xenograft models of neuroblastoma [127, 128] . However, the cmap networks are valuable outside of cancer as well. For instance, Loboda et al. intersected signatures of natural diurnal variation in metabolism, the effects of the weight loss drug sibutramine and genes repressed by two mTOR inhibitors in the cmap, supporting the relationship between sibutramine and diurnal variation in metabolism and identifying a previously unappreciated relationship between mTOR signaling and circadian variation in metabolism [129] . This intersection of drug signatures from cmap with other gene-expression signatures and networks is one of the most promising applications of the cmap data since it can test the ability of the highly controlled, cell line cmap data for a broad collection of drugs to generalize to whole organisms under less controlled conditions. One can imagine that the combination of modern, comprehensive cmap drug signatures with eQTL linking to a particular locus should yield results even more informative than those discriminating the effects of rosiglitazone and a Alox5-targeted mutation through intersection with metabolic QTL and associated eQTL in a mouse cross [55] . Similar benefit would be expected by intersecting cmap, NCI60
and HapMap cell line data with many of the other recently developed network models discussed in this review. Since many cmap-derived results have yet to be widely replicated, it will be interesting over time to catalog which cellular phenotypes and networks underlying them are robust across laboratories and which consistently reproduce biology of whole tissues and organisms; key questions that define the utility of any laboratory or computational model of biology.
Networks potentially useful for pharmacogenomics have also been built around diseases and symptoms. Initially, these were text-mining applications on semi-structured databases such as Online Mendelian Inheritance in Man [130, 131] , and Medical Subject Headings [132] . Because of their less quantitative nature they were useful in generating hypotheses regarding links between diseases, disease mechanisms and potential therapeutic approaches. However, as more quantitative and systematic data has become accessible for each disease, more quantitative approaches to describe relationships between diseases that leverage annotated gene-expression profiles and combinations of annotated gene-expression profiles with protein-protein interaction data have become available [133, 134] . These most recent efforts show robust statistical relationships between networks associated with particular diseases and the drugs used to treat them, and provide testable, quantitative hypotheses about which drugs will be useful for which diseases.
These disease networks, however, at present lack a description of the individual-level variability we customarily think about when discussing pharmacogenomics since they, by definition, treat each disease as a coherent whole. This is beginning to change, however, in two ways. First, as more molecular and clinical data are available for patients on each disease, it is becoming possible to subtype diseases more precisely. For instance, cardiovascular health is now routinely assessed through the measurement of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, C-reactive protein, blood glucose and HBA1c, triglycerides and blood pressure [135, 136] . It may even include an imaging component if disease is suspected [137] . In total, this data, measured over time, represents far more information than was routinely available on patients in the past, and can in theory be used to identify patient populations with distinct subtypes of cardiovascular disease. However, it is clear that most studies intended to test enhancements to standard risk prediction tools such as the Framingham Risk Score have to date not future science group
Integrative genomics strategies to elucidate the complexity of drug response Review been performed with designs rigorous enough to exploit this information on its own [138] , underscoring the potential value of analyzing clinical measurements in the context of genetic information and network models derived from molecular measurements across populations. In cancer, where important molecular subtypes of cancers have long been recognized, there is a similar growth in the molecular and other information available on tumors [139] [140] [141] . Second, obtaining a good picture of a patient's genetic information is becoming increasingly routine. This has long been instrumental in the characterization of Mendelian disorders, but is now routine for common diseases such as Alzheimer's disease, where the ApoE genotype has long been appreciated to be strongly associated with age of onset and course of disease [142] , and recent GWAS have now implicated a number of loci that appear relevant to immune function, cell membrane function and lipid metabolism [143, 144] . The recent advent of inexpensive genome sequencing will also make such determinations possible for many diseases and be a significant aid to diagnosis, as has already been shown in the genetic differential diagnosis of Bartter's syndrome and congenital chloride diarrhea [145] . A combination of multifactorial molecular, clinical and genetic parameters measured in an individual patient generates a comprehensive profile of that patient. As data and network models grows more complete and better organized, this suggests an opportunity to compare that individual's profile to a reference collection of network models built from population-level data to derive increasingly tailored lifestyle and therapeutic interventions for that individual (Figure 4) .
Nowhere is the potential impact of integrative genomics approaches to pharmacogenomics greater than in cancer. Tumors are frequently accessible for molecular investigation, and their great diversity in symptoms and response to therapy provide strong motivation to apply pharmacogenomics approaches. Hence, many projects are underway across the globe to characterize, at the molecular level, many of these individual tumor types [146, 147] . A hint of where this rich information may lead is provided by a case study in glioblastoma. Early work based entirely on gene-expression profiling of highgrade gliomas led to the identification of three subtypes, of which the mesenchymal subtype had the worst prognosis, with post-treatment survival as the end point [148, 149] . Application of the Algorithm for the Reconstruction of Accurate Cellular Networks to define modules of genes related by coexpression, followed by the Master Regulator Inference algorithm to search for transcriptional regulators of these modules identified a hierarchical grouping of transcription factors that controlled more than 74% of the transcription in the mesenchymal signature [150] . This regulatory structure was then supported by chromatin immunoprecipitation in a human glioma cell line, gain and loss of function experiments in cell lines and tumor production in mice. Importantly, high expression of master regulators of this mesenchymal signature, Stat3 and C/EBPb, increased markers of tumor aggressiveness in all these assays and decreased survival of human glioma patients [150] . With several other glioblastoma data sets containing coherent molecular and clinical information now available, there will be many opportunities to refine the structure of these predictive networks and test their reproducibility across different sets of patients [149, 151, 152] . These genes will undoubtedly also be investigated by copy number variation analysis in glioblastomas, and the Cancer Targeted Discovery and Development Network (CTD2) program is seeking small molecule validation of these targets as well [146] . Impressive as these results are, the data on which they are based is scant and imprecise in comparison to Measurements in individuals of biological network states using acute laboratory tests or longitudinal mining of clinical data will reveal motifs that map to known disease-and treatment-associated network modules determined from population-based studies. Here, the motifs are shown as the small networks next to the individuals in the upper corners of the figure, and they map to subnetworks outlined in red within the encircled reference modules at the center of the figure. These reference modules were derived from studies of populations that did not include the individuals shown in this figure. This mapping of motif to module subnetwork can then in principal be used to guide individualized recommendations for pharmacological and lifestyle interventions.
future science group Review Kasarskis, Yang & Schadt what is coming. Already, it is cost effective to sequence adjacent normal and tumor tissue for some research studies [205] , something that was a noteworthy achievement as recently as 2010 [153] , and collections of hundreds of cancer genomes have been analyzed in combination to identify networks of genes not previously implicated in distinct cancer types [154, 155] . This rich information will surely allow us to make much better predictions about which of an increasing array of targeted cancer therapies are appropriate for a given cancer patient. The difficulty of getting clinical benefit from such predictions is not to be underestimated, however. First, these results have not yet been widely confirmed in many independent cohorts. Second, many factors combine to make introduction of genomic information into clinical settings a challenging and time consuming process in general, and the huge diversity of individual tumors make each case a unique challenge to each individual patient and his or her physicians that require detailed and comprehensive investigation to understand, interpret and present [156, 157] .
Conclusion & future perspective
At present, there are no real examples of moving prospectively from biological network approaches to diversity of drug response in humans. This contrasts with many strong examples of prospective drug-target discovery by network methods and is certainly a reflection of the fact that the clinical studies take time to complete. However, our ability to access large amounts of clinical data in a structured way to rigorously test hypotheses stemming from integrative genomics approaches in the clinic is improving rapidly and should become routine in at least some cases within the next 5-10 years. Even modest improvements in data capture, such as those investigating the pharmacogenomics of cisplatin-induced deafness, hydrocodone toxicity and other drugs through a focused effort in Canada clearly shows the benefit of a focused search for drug reactions in an ambulatory population [158] [159] [160] [161] . Although moving more slowly than many would like, there is a global trend towards increased electronic data capture into electronic medical records (EMRs) and higher quality of the coding in those EMRs [162, 163] . As more and more EMR data become available, it will be a well-powered resource for mining in combination with the increasingly precise and voluminous molecular data made cheaply available by advances in sequencing technology.
One widely quoted estimate is that over 10,000 human genomes will have been sequenced worldwide by the end of 2011, in comparison with tens of human genomes at the end of 2009 [164] , and that genome sequencing will start to make an appearance in clinical diagnosis [145, 165, 166] . In combination with what is likely to be a substantially even greater number of RNA-Seq experiments as well as existing volumes of other high information content medical data such as images, EEGs and ECGs, this represents a vast set of data to be mined. Add to that the likely advances in all manner of sensor technologies and potentially better descriptions of social and environmental interactions that leverage our increasing documentation of our activities online, and there is clearly a demand to apply both the lessons in data management and mining that have been learned from large internet firms and to develop analytical and data mining methods specific to biological and health data [167] [168] [169] 206, 207] . Although they will surely be viewed as infant steps a decade from now, we are nevertheless seeing progress in both areas. For instance, an analysis optimized to minimize the multiple-testing issues of a GWAS demonstrated well over an order of magnitude improvement in the ratio of true to false-positive marker-trait associations [170] . Similarly, mining even a relatively small hospital's EMR demonstrated a clear retrospective association between rosiglitazone and COX-2 inhibitors and adverse cardio vascular outcomes [171, 172] . Clearly, the potential benefits of postmarket surveillance in the coming information-rich heathcare environment are on par with the potential benefits in discovery of new therapeutic modalities and their individualized and cost-effective application to appropriate patient subpopulations. Properly harnessed, better capture and open sharing of clinical measurements, environmental conditions, social circumstances and molecular phenotypes of patients hold out the possibility of better health and safer, more effective therapies.
What stands in the way of this vision? Although there are technological challenges to delight legions of clever people in fields as diverse as computer science, clinical medicine, pharmacology, genetics, economics, epidemiology, nanotechnology and statistics, it is our opinion that those will be overcome in a reasonably efficient way if sufficient data is openly available to address challenges as they appear. Rather, the main barriers to realizing the promise of truly integrating genomic technologies with information-rich medical practice will be social. Data from research studies need to be captured and accessible for reuse future science group
Integrative genomics strategies to elucidate the complexity of drug response Review by future investigators, but this is neither widely instilled across the academic community nor funded by most research sponsors. The security and rights of individuals cannot be compromised if their medical, molecular and other data are used in research, and this is not easy to achieve, let alone harmonize internationally to support the sort of global collaborative efforts that are a natural consequence of intersecting data with whatever other information is most constructive in gaining new insight. Perhaps most difficult is the fact that humans have never before been confronted with so much definite information on health and prognosis as the coming data and decision support systems built on it will eventually provide. Figuring out what interventions to pursue as a consequence of this information and determining who pays for it all in the fragmented healthcare delivery systems across much of the world are nontrivial undertakings. These social challenges do not have to be resolved all at once or immediately; however, the benefits of a systems approach to pharmacotherapy will be paced by how successfully they are addressed. 
Executive summary

Full mechanisms behind pharmacogenomic effects are often opaque
Although there are well-understood examples of pharmacogenetic effects with drugs such as clopidogrel, warfarin, abacavir, flucloxacilin and others, it is frequently difficult to obtain a solid understanding of the full mechanism by which genetics affects the action of a drug. Even when a mechanism is understood, there is other variation in drug response that is not explainable by that mechansim, so there is an opportunity to apply integrative genomics approaches that leverage relationships frequently observed between genes, drugs, diseases and other concepts in population studies.
Fuctional genomics & network biology
Genetics of gene expression and other techniques for relating genetic variation and gene level or activity often suggest mechanisms underlying associations between genetic variation and drug effects in genome-wide association studies. This has been observed for warfarin, lumiracoxib, flucloxacilin and statins, demonstrating that the genetics of gene expression has general utility to probe pharmacogenetic associations. Incorporation of Bayesian and weighted gene coexpression network analysis methods routinely used to structure the ana lysis and application of functional genomics data enhances the interpretation of disease-related genome-wide association study results.
Integrative genomics of the human liver
Networks derived from genetics of gene expression in human liver demonstrate many genes robustly associated with the function and activity of CYP450s. Human and mouse networks, used in combination, identify previously unappreciated potential regulators of CYP450s and can be used to address other liver-expressed genes of pharmacogenomic interest in an analogous manner.
Other integrative genomics approaches to data
Networks built from other data combinations are also tools with the potential to improve our understanding of any given drug response. Notable examples include systematic cell-based connectivity map screening approaches that marry drug effects on cells with gene expression in those cells, copy number variation analysis of tumors with gene expression and clinical end points and database mining of clinical records and the published literature in combination with public molecular data repositories.
Conclusion & future perspective
Although functional genomics approaches have shown benefit in understanding pharmacogenetic associations for several drugs, at present we lack examples of going prospectively from biological network models to diversity of drug response in humans. This contrasts with many examples of target discovery, and we anticipate that prospective evidence for the utility of these approaches to drug response will emerge as the lengthy process of clinical testing progresses. Data relevant to pharmacogenomics will become ubiquitous with improved clinical data capture in electronic medical records, affordable personal genomes and the continued development of new technologies for assaying and imaging patients in a near-continuous fashion. Fortunately, better analytics coupled to increasingly available computing power will enable better discrimination of informative patterns in all this data and their application to clinical practice.
If coupled with open-data availability and sharing of materials needed to replicate laboratory results, these trends promise not only more effective use of existing therapeutics, but also less expensive and more rapid development of new therapies, including conventional drugs as well as, or in combination with, other therapeutic modalities.
